FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016373265> ?p ?o ?g. }

• W2016373265 endingPage "4272" @default.
• W2016373265 startingPage "4267" @default.
• W2016373265 abstract "Abstract This phase 2 study evaluated the safety and efficacy of alemtuzumab in 22 patients with advanced mycosis fungoides/Sézary syndrome (MF/SS). Most patients had stage III or IV disease, reduced performance status, and severe itching. The overall response (OR) rate was 55%, with 32% of patients in complete remission (CR) and 23% in partial remission (PR). Sézary cells were cleared from the blood in 6 of 7 (86%) patients, and CR in lymph nodes was observed in 6 of 11 (55%) patients. The effect was better on erythroderma (OR, 69%) than on plaque or skin tumors (OR, 40%) and in patients who had received 1 to 2 previous regimens (OR, 80%) than in those who had received 3 or more prior regimens (OR, 33%). Itching, self-assessed on a 0 to 10 visual analog scale, was reduced from a median of 8 before treatment to 2 at end of therapy. Median time to treatment failure was 12 months (range, 5-32+ months). Cytomegalovirus (CMV) reactivation (causing fever without pneumonitis and responding to ganciclovir) occurred in 4 (18%) patients. Six additional patients had suspect or manifest infection (fever of unknown origin, 3; generalized herpes simplex, 1; fatal aspergillosis, 1). One patient had fatal Mycobacterium pneumonia at 10+ months. All serious infectious adverse events (except CMV) occurred in patients who had received 3 or more prior regimens. Progression of squamous cell skin carcinoma was noted in 1 patient. Alemtuzumab shows promising clinical activity and an acceptable safety profile in patients with advanced MF/SS, particularly in patients with erythroderma and severe itching and those who were not heavily pretreated." @default.
• W2016373265 created "2016-06-24" @default.
• W2016373265 creator A5005823323 @default.
• W2016373265 creator A5016053082 @default.
• W2016373265 creator A5016639606 @default.
• W2016373265 creator A5028207200 @default.
• W2016373265 creator A5040624896 @default.
• W2016373265 creator A5043417410 @default.
• W2016373265 creator A5049924304 @default.
• W2016373265 creator A5050258103 @default.
• W2016373265 creator A5077837562 @default.
• W2016373265 creator A5081318080 @default.
• W2016373265 date "2003-06-01" @default.
• W2016373265 modified "2023-09-29" @default.
• W2016373265 title "Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome" @default.
• W2016373265 cites W1506762754 @default.
• W2016373265 cites W1542628397 @default.
• W2016373265 cites W1833241997 @default.
• W2016373265 cites W1889167126 @default.
• W2016373265 cites W1895474562 @default.
• W2016373265 cites W1896729546 @default.
• W2016373265 cites W1954038871 @default.
• W2016373265 cites W1974738881 @default.
• W2016373265 cites W1977898643 @default.
• W2016373265 cites W1983223760 @default.
• W2016373265 cites W1986728257 @default.
• W2016373265 cites W1987203409 @default.
• W2016373265 cites W1988679162 @default.
• W2016373265 cites W1989053318 @default.
• W2016373265 cites W1993845235 @default.
• W2016373265 cites W2006103885 @default.
• W2016373265 cites W2015421929 @default.
• W2016373265 cites W2020904611 @default.
• W2016373265 cites W2045733649 @default.
• W2016373265 cites W2046110140 @default.
• W2016373265 cites W2078277756 @default.
• W2016373265 cites W2087742242 @default.
• W2016373265 cites W2089790910 @default.
• W2016373265 cites W2108276207 @default.
• W2016373265 cites W2115782311 @default.
• W2016373265 cites W2137243379 @default.
• W2016373265 cites W2138191719 @default.
• W2016373265 cites W2143749371 @default.
• W2016373265 cites W2150604820 @default.
• W2016373265 cites W2155652724 @default.
• W2016373265 cites W2168799171 @default.
• W2016373265 cites W2169167811 @default.
• W2016373265 cites W2261126455 @default.
• W2016373265 cites W233460929 @default.
• W2016373265 cites W2337557724 @default.
• W2016373265 cites W4249049999 @default.
• W2016373265 cites W74992319 @default.
• W2016373265 cites W83807906 @default.
• W2016373265 doi "https://doi.org/10.1182/blood-2002-09-2802" @default.
• W2016373265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12543862" @default.
• W2016373265 hasPublicationYear "2003" @default.
• W2016373265 type Work @default.
• W2016373265 sameAs 2016373265 @default.
• W2016373265 citedByCount "363" @default.
• W2016373265 countsByYear W20163732652012 @default.
• W2016373265 countsByYear W20163732652013 @default.
• W2016373265 countsByYear W20163732652014 @default.
• W2016373265 countsByYear W20163732652015 @default.
• W2016373265 countsByYear W20163732652016 @default.
• W2016373265 countsByYear W20163732652017 @default.
• W2016373265 countsByYear W20163732652018 @default.
• W2016373265 countsByYear W20163732652019 @default.
• W2016373265 countsByYear W20163732652020 @default.
• W2016373265 countsByYear W20163732652021 @default.
• W2016373265 countsByYear W20163732652022 @default.
• W2016373265 countsByYear W20163732652023 @default.
• W2016373265 crossrefType "journal-article" @default.
• W2016373265 hasAuthorship W2016373265A5005823323 @default.
• W2016373265 hasAuthorship W2016373265A5016053082 @default.
• W2016373265 hasAuthorship W2016373265A5016639606 @default.
• W2016373265 hasAuthorship W2016373265A5028207200 @default.
• W2016373265 hasAuthorship W2016373265A5040624896 @default.
• W2016373265 hasAuthorship W2016373265A5043417410 @default.
• W2016373265 hasAuthorship W2016373265A5049924304 @default.
• W2016373265 hasAuthorship W2016373265A5050258103 @default.
• W2016373265 hasAuthorship W2016373265A5077837562 @default.
• W2016373265 hasAuthorship W2016373265A5081318080 @default.
• W2016373265 hasBestOaLocation W20163732651 @default.
• W2016373265 hasConcept C126322002 @default.
• W2016373265 hasConcept C16005928 @default.
• W2016373265 hasConcept C2776694085 @default.
• W2016373265 hasConcept C2777063308 @default.
• W2016373265 hasConcept C2777714996 @default.
• W2016373265 hasConcept C2777756187 @default.
• W2016373265 hasConcept C2779015954 @default.
• W2016373265 hasConcept C2779338263 @default.
• W2016373265 hasConcept C2779524853 @default.
• W2016373265 hasConcept C2911091166 @default.
• W2016373265 hasConcept C71924100 @default.
• W2016373265 hasConcept C90924648 @default.
• W2016373265 hasConceptScore W2016373265C126322002 @default.
• W2016373265 hasConceptScore W2016373265C16005928 @default.
• W2016373265 hasConceptScore W2016373265C2776694085 @default.

• next